Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q4 2018 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$6.58M$6.58Mderived+64.2% vs Q4 2017 Net Income-$109.91K-$109.91KderivedN/M vs Q4 2017 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Cash Flowderived$932,761+17,803.3% Free Cash Flowderived$921,530N/M Margins · derivedNet margin-1.7%+4.2 pt vs Q4 2017
ended Dec 31, 2018 · filed Mar 12, 2019 · 71 d after period end